David Khayat

Gabriel N. Hortobagyi

This is the fourth volume of our series Progress in Anti-cancer Therapy. For the past four years we have taken the challenge to select each year, some of the most interesting topics on the wide field of oncology. As usual, this volume continues the tradition and covers five cancers (breast, prostate, bladder, lym phoma and ovarian), the role of HIV and HTLV in cancer, as well as some deve lopmental pharmacology and behavioral issues. This year, we have particularly focused our attention on one of the most com mon (although rarely addressed) cancer accounting for more than 315,00 newly diagnosed cases and 41,000 cancer-related deaths annually (Landis SH et al., 1999) : prostate cancer. Five chapters address some of the issues concerning this disease. The chap ter by Schroder describes the hopes and pitfalls of early detection of prostate cancer. It reviews the literature on screening studies that have been performed both in the US and in Europe. These studies suggest that cancer mortality could be reduced by screening for prostate cancer, mostly through PSA testing. However, the effectiveness of early detection still needs to be definitely confir med and ongoing randomized studies are described, the results of which will probably help the medical community determine the worth of PSA-based scree ning for prostate cancer. On the same hand, the paper from von Eschenbach is reviewing the clinical problems that are related this disease.

Progress in Anti-Cancer Chemotherapy

Jeffrey S. Ross

Jeffrey Stuart Ross

The first comprehensive reference to focus on the molecular development and treatment of the disease, Molecular Oncology of Breast Cancer provides authoritative information across the spectrum of modern breast cancer research and clinical care. Edited by two world-class experts in cancer pathology, drug development, and patient management, with contributions from over 50 experts, this ground-breaking text describes the genes, proteins, and biologic pathways that are being evaluated today and will be tested in the future to derive the molecular signature of each newly diagnosed breast cancer. For the first time, readers can now obtain, in a single volume, up-to-date information on how molecular-based tests are being used to identify predisposition, provide earliest detection, decide classification based on genetic fingerprint and predict therapy-specific outcomes. MOBC includes unique chapters on functional imaging and the impact of targeted therapies on the FDA approval process. This book gives readers vital, up-to-date information on important molecular discoveries that affect the everyday management of the breast cancer patient.

Molecular Oncology of Breast Cancer

Geoffrey L. Robb

The information surveyed in this volulme is designed to provide the clinician with an expert overview of the current state of the art in breast cancer management. It should provide at least a flavor of the major paradigm shift that is occurring in this rapidly evolving field. Breast cancer management is moving away from a "kill or cure" model and advancing toward a model focused on strategies of prevention and of long-term management of breast cancer as a chronic disease. The acceptance of this new paradigm by patients and clinicians alike will represent a major focus for the twenty-first century.

Advanced Therapy of Breast Disease

Pinuccia Valagussa

Gianni Bonadonna

With the current advances in chemotherapy and hormonal drugs for breast cancer, as well as in surgical techniques and procedures, a revised edition of this popular textbook has become increasingly necessary. Completely overhauling the existing material, the editors of this important work have provided a full update of the area, focusing in particular upon the topics where there has been most progress and controversy.

A Clinical Guide to Therapy

Textbook of Breast Cancer

This is the third volume of our series Progress in Anti-Cancer Chemo therapy. Following the strategy of the first two volumes, it covers selected aspects of progress in this fast moving field of Oncology, with contribu tions from some of the world's best known leaders in both basic and clin ical research. This year we focused on seven areas: Three prominent Clinical investigators reviewed conceptual advances in cancer research. Dr Buzdar presented a history and overview of the protection of human subjects who participate in clinical research, and the mechanisms developed to assure the ethical conduct of research on human beings. Frei reviewed an exciting and rapidly moving area of che motherapy of solid tumors, including a cogent discussion of the issues related to dose-intensification. Fisher summarized conceptual advances in our therapeutic approach to breast cancer and the paradigm shifts that lead us to our current management strategies. From this summary he pro jected breast cancer research into the future, a daunting task under any circumstance. Fundamental research in cancer biology has been responsible for our improved understanding of the development and progession of malignant disease. Such understanding will lead to improved diagnosis, therapy, and eventually, prevention. Isaacs reviews the area of hereditary breast cancer, a topic undergoing rapid transformation and with mUltiple impli cations in the daily practice of medicine. Fidler, an international expert in metastasis research reviews the potential utility of angiogenesis inhib itors in research and the therapeutic ramifications.

Gabriel N. Hortobagyi

About

Books

Join the club